A brain stimulation device just approved by the US Food and Drug Administration (FDA) was developed as part of a multi-site clinical study led by University of Minnesota medical researchers and partly funded by the MnDRIVE program. According to Twin Cities Business, neurology department chair Dr. Jerrold Vitek and his research team successfully implanted the first non-trial patient with the Vercise system at the University of Minnesota Medical Center in December. The device is manufactured by Boston Scientific, and has been hailed as “one the most innovative neuromodulation technologies available today.” Deep brain stimulation is used to reduce the involuntary shaking and stiffness that are among the symptoms of Parkinson's disease. MnDRIVE – Minnesota’s Discovery, Research, and InnoVation Economy – is a partnership between the University and the State of Minnesota that aligns areas of research strength with the state’s key and emerging industries. One of of MnDRIVE's areas of focus is the treatment of brain conditions; the others are robotics, global food and the environment.
Wednesday, January 10, 2018